Ariel Nelson
Overview
Explore the profile of Ariel Nelson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
151
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mirsky M, Mitchell C, Hong A, Cao S, Fu P, Margevicius S, et al.
Cancer Manag Res
. 2023 Sep;
15:913-927.
PMID: 37674660
Purpose: Disparities in cancer care delivery remain a pressing health-care crisis within the United States (US). The use of immune checkpoint inhibitors (ICIs) and their management may be a disparity...
2.
Kim A, Nelson A, Stimpert K, Flyckt R, Thirumavalavan N, Baker K, et al.
JCO Oncol Pract
. 2022 Sep;
18(12):815-822.
PMID: 36174117
Immune checkpoint inhibition has resulted in significant efficacy across many cancer types, including melanoma. Melanoma is the second most common cancer among those of reproductive age, yet the reproductive toxicities...
3.
Talukder R, Makrakis D, Lin G, Diamantopoulos L, Dawsey S, Gupta S, et al.
Clin Genitourin Cancer
. 2022 Sep;
20(6):558-567.
PMID: 36155169
Background: Early progression on first-line (1L) platinum-based therapy or between therapy lines may be a surrogate of more aggressive disease and poor outcomes in advanced urothelial carcinoma (aUC), but its...
4.
Makrakis D, Talukder R, Lin G, Diamantopoulos L, Dawsey S, Gupta S, et al.
Clin Genitourin Cancer
. 2022 Jul;
20(5):e440-e452.
PMID: 35778337
Background: Sites of metastasis have prognostic significance in advanced urothelial carcinoma (aUC), but more information is needed regarding outcomes based on metastatic sites in patients treated with immune checkpoint inhibitors...
5.
Talukder R, Makrakis D, Diamantopoulos L, Carril-Ajuria L, Castellano D, de Kouchkovsky I, et al.
Clin Genitourin Cancer
. 2022 Jan;
20(2):165-175.
PMID: 35078711
Background: Immune checkpoint inhibitors (ICI) improve overall survival (OS) in patients with locally advanced, unresectable, or metastatic urothelial carcinoma (aUC), but response rates can be modest. We compared outcomes between...
6.
Makrakis D, Talukder R, Diamantopoulos L, Carril-Ajuria L, Castellano D, de Kouchkovsky I, et al.
BJU Int
. 2021 Oct;
130(5):592-603.
PMID: 34597472
Objectives: To compare clinical outcomes with programmed-death ligand-1 immune checkpoint inhibitors (ICIs) in patients with advanced urothelial carcinoma (aUC) who have vs have not undergone radical surgery (RS) or radiation...
7.
Dubey S, Singh M, Nelson A, Karan D
J Immunol Res
. 2021 Sep;
2021:9483433.
PMID: 34485538
Medicinal plants serve as a lead source of bioactive compounds and have been an integral part of day-to-day life in treating various disease conditions since ancient times. Withaferin A (WFA),...
8.
Hall W, Bedi M, Kilari D, Bylow K, Burfeind J, Johnstone C, et al.
Pract Radiat Oncol
. 2021 Apr;
11(6):527-533.
PMID: 33848618
Purpose: There remains limited data as to the feasibility, safety, and efficacy of higher doses of elective radiation therapy to the pelvic lymph nodes in men with high-risk prostate cancer....
9.
Esagian S, Khaki A, Diamantopoulos L, Carril-Ajuria L, Castellano D, de Kouchkovsky I, et al.
BJU Int
. 2021 Feb;
128(2):196-205.
PMID: 33556233
Objectives: To compare clinical outcomes between patients with locally advanced (unresectable) or metastatic urothelial carcinoma (aUC) in the upper and lower urinary tract receiving immune checkpoint inhibitors (ICIs). Patients And...
10.
Khaki A, Li A, Diamantopoulos L, Miller N, Carril-Ajuria L, Castellano D, et al.
Eur Urol Oncol
. 2021 Jan;
4(3):464-472.
PMID: 33423945
Background: While immune checkpoint inhibitors (ICIs) are approved in the first-line (1L) setting for cisplatin-unfit patients with programmed death-ligand 1 (PD-L1)-high tumors or for platinum (cisplatin/carboplatin)-unfit patients, response rates remain...